A recent report from the Advisory Council on the Misuse of Drugs (ACMD) addresses the treatment of hepatitis C amongst people who use heroin.
The report explores how hepatitis C could be eliminated amongst people in drug treatment
and how the variations in access to treatment for hepatitis C reduces the likelihood of successful outcomes from drug treatment. Entitled ‘How can opioid substitution therapy be optimised to maximise recovery outcomes for service users?’ the report states that ‘the new treatment regimens for hepatitis C could result in the vast majority becoming free of the hepatitis C virus.’
The prevalence of hepatitis C amongst people who inject drugs in the UK is estimated to be 50% and as a group they represent 80% of those living with the virus in the UK.
Despite this ‘the ACMD is particularly concerned that access to evidence-based health treatment for both mental health problems and now treatable hepatitis C, appears to be variable.’